My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

127.62 +0.44 (+0.35%)

Streaming Delayed Price Updated: 10:15 AM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

67 68 Next >

Which S&P500 stocks are gapping on Wednesday? ↗

March 19, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding ↗

March 19, 2025

HIV prevention is a staple in Gilead Sciences' wheelhouse.

Via Investor's Business Daily

Wednesday's pre-market session: top gainers and losers in the S&P500 index ↗

March 19, 2025

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

Via Chartmill

Crypto Mixed Post Trump-Putin Call; Trump Eyes HIV Program Cuts, Gilead Dips; Nvidia's AI Lead Secure Through 2028, Says JPMorgan – Top Headlines While The U.S. Slept ↗

March 19, 2025

Via Benzinga

Topics Artificial Intelligence Government

The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts ↗

March 11, 2025

Via Benzinga

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

March 10, 2025

Via Benzinga

P/E Ratio Insights for Gilead Sciences ↗

March 07, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

March 06, 2025

Via Benzinga

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides ↗

March 19, 2025

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the...

Via Benzinga

Topics Government

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Unpacking the Latest Options Trading Trends in Gilead Sciences ↗

March 18, 2025

Via Benzinga

Gilead Sciences - Leader In HIV Medicines ↗

March 14, 2025

The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.

Via Talk Markets

Topics Stocks / Equities

Gilead Sciences Unusual Options Activity ↗

February 24, 2025

Via Benzinga

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Is Gilead Sciences Gaining or Losing Market Support? ↗

March 13, 2025

Via Benzinga

GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why. ↗

March 13, 2025

A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors.

Via Chartmill

Gilead Presents New HIV Treatment And Cure Research Data ↗

March 12, 2025

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.

Via Benzinga

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

March 12, 2025

From Gilead Sciences, Inc.

Via Business Wire

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

March 11, 2025

From Gilead Sciences, Inc.

Via Business Wire

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

March 11, 2025

Via MarketBeat

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 11, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI) ↗

March 11, 2025

Via The Motley Fool

Topics Artificial Intelligence

1 Value Stock with Exciting Potential and 2 to Ignore

March 10, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Best And Worst Performing S&P 500 Stocks Since Trump's Election Win ↗

March 07, 2025

Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.

Via Benzinga

Topics Government Stocks

Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook. ↗

February 26, 2025

Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products.

Via Investor's Business Daily

Topics Artificial Intelligence

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

February 24, 2025

From Gilead Sciences, Inc.

Via Business Wire

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

February 23, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

Via StockStory

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

February 22, 2025

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Via MarketBeat

Topics Death

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

67 68 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.